All News
Today is April 26, 2018.
All times in Eastern Daylight Time.
-
Alzheon Launches Roadshow for Initial Public Offering
FRAMINGHAM, Mass.--(EON: Enhanced Online News)--Alzheon, Inc. (“Alzheon”) announced today that it has launched the roadshow for the initial public offering of its common stock. Alzheon is offering ... more » -
Alzheon ALZ-801 Data Presented in Oral Session at CTAD on Role of Amyloid Oligomers in Alzheimer’s Disease
FRAMINGHAM, Mass.--(EON: Enhanced Online News)--Alzheon presents ALZ-801 data in oral session on the role of amyloid oligomers in Alzheimer’s Disease 10th Clinical Trials on Alzheimer’s Disease mtg. more » -
Alzheon Publishes Clinical Results that Demonstrate Safety Profile and Efficacy Potential of ALZ-801 as an Orally-Available Precision Medicine to Treat Alzheimer’s Disease
FRAMINGHAM, Mass.--(EON: Enhanced Online News)--Alzheon, Inc. published clinical results demonstrating safety profile and efficacy potential of ALZ-801 for Alzheimer’s disease. more » -
FDA Grants Fast Track Designation to Alzheon’s ALZ-801 Development Program for the Treatment of Alzheimer’s Disease
FRAMINGHAM, Mass.--(EON: Enhanced Online News)--Alzheon, Inc. announced that FDA has granted Fast Track designation to its lead clinical investigational drug, ALZ-801, for Alzheimer’s disease. more » -
Alzheon to Make Presentations on ALZ-801 and Its Anti-Oligomer Mechanism at the 10th Clinical Trials on Alzheimer’s Disease Congress
FRAMINGHAM, Mass.--(EON: Enhanced Online News)--Alzheon will make three presentations at the 10th Annual Clinical Trials on Alzheimer’s Disease (CTAD) congress to be held on November 1‐4 in Boston. more » -
Alzheon to Make Keynote and Featured Presentations at Upcoming Scientific and Industry Conferences
FRAMINGHAM, Mass.--(EON: Enhanced Online News)--Alzheon will be making keynote and featured presentations at several scientific, business and drug development conferences in the Fall. more » -
Alzheon Presents New Data for Lead Candidate ALZ-801 on Novel MOA and Long-Term Clinical Efficacy at the Alzheimer’s Association International ConferenceFRAMINGHAM, Mass.--(EON: Enhanced Online News)--Alzheon announced data from the company’s three presentations at the Alzheimer’s Association International Conference (AAIC) in London. more »
-
Alzheon Publishes New Analyses Showing Clinical Benefit of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer’s Disease; Clinical Effects Suggest Disease Modification and Align with Beta Amyloid Oligomer Formation
FRAMINGHAM, Mass.--(EON: Enhanced Online News)--Alzheon publishes analyses showing clinical benefit of Tramiprosate in APOE4/4 Homozygous patients at the mild stage of Alzheimer’s disease in JPAD. more » -
Alzheon to Present Novel Molecular Mechanism of Action and Long Term Clinical Efficacy Data for Lead Candidate ALZ-801 at the Alzheimer’s Association International Conference
FRAMINGHAM, Mass.--(EON: Enhanced Online News)--Alzheon to present novel molecular MOA and long term clinical efficacy data for lead candidate ALZ-801 at Alzheimer’s Association International Conf. more »
Contact Us
For more information, visit the Contact Us page of BusinessWire.com to find a bureau near you.